PYPD Stock Summary and Trading Ideas (Polypid Ltd. - | NASDAQ:PYPD)

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

Polypid Ltd. - trades on the NASDAQ stock market under the symbol PYPD.

As of June 5, 2026, PYPD stock price declined to $4.50 with 214,056 million shares trading.

PYPD has a beta of 1.47, meaning it tends to be more sensitive to market movements. PYPD has a correlation of 0.21 to the broad based SPY ETF.

PYPD has a market cap of $45.86 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, PYPD traded as high as $13.20 and as low as $2.30.

PYPD has outperformed the market in the last year with a return of +42.4%, while the SPY ETF gained +25.6%. However, in the most recent history, PYPD shares have underperformed the stock market with its stock returning +6.4% in the last 3 month period and -10.4% for the last 2 week period, while SPY has returned +8.5% and -1.1%, respectively.

PYPD support price is $4.63 and resistance is $5.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PYPD shares will trade within this expected range on the day.